Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193755 | 0.83 | BRAF (0.53) | MEN1KMT2ABRAFNPC1RAB9A | |
| SCHEMBL2193789 | 0.81 | BRAF (0.46) | MEN1KMT2ABRAFNPC1RAB9A | |
| SCHEMBL2190481 | 0.81 | NPC1 (0.60) | MEN1KMT2ABRAFNPC1RAB9A | |
| SCHEMBL29878139 | 0.80 | BRAF (0.52) | MEN1KMT2ABRAFNPC1RAB9A | |
| SCHEMBL2194286 | 0.79 | BRAF (0.52) | MEN1KMT2ABRAFNPC1RAB9A | |
| SCHEMBL2817545 | 0.78 | NPC1 (0.71) | MEN1KMT2ABRAFNPC1RAB9A | |
| SCHEMBL11675529 | 0.78 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL6793906 | 0.78 | MEN1 (0.93) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL29800565 | 0.78 | MEN1 (0.93) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL1008115 | 0.78 | KMT2A (0.45) | KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20100016351-A1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | NGUYEN TRUC MINH | 2010-01-21 | — | — | US | disclosed |
| EP-1828179-B1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AGAINST CNS-RELATED DISEASES | MEMORY PHARM CORP (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7625924-B2 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1828179-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | Memory Pharmaceutical Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2006069097-A2 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | MEN1 627/4885KMT2A 974/4885BRAF 1/4885 |
| US-20060167039-A1 | Nicotinic alpha-7 receptor ligands and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA6 | MEN1 3515/4885KMT2A 3536/4885BRAF 4455/4885 |
| US-20100016351-A1 | NICOTINIC ALPHA-7 RECEPTOR LIGANDS AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA6 | MEN1 3515/4885KMT2A 3536/4885BRAF 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.